News | April 26, 2024
Merck 1Q 2024 sales up 9% to US$ 15.8 billion
Sales reflect continued strong growth in oncology and vaccines
Sales reflect continued strong growth in oncology and vaccines
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Subscribe To Our Newsletter & Stay Updated
